Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...

Unity Biotechnology Inc (NASDAQ:UBX) stock has reached a 52-week high, trading at $2.02, signaling a period of robust ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Unity Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 76.03%. The profit margin, also known as the revenue ratio or gross profit ratio ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy recommendation. Analyst Price Forecast Suggests 277.88% Upside As of ...

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic ...

OpenAI CEO Sam Altman backs Retro Biosciences, a San Francisco-based biotech start-up that wants to extend human lifespan by ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

Sam Altman, the CEO of OpenAI, is backing a groundbreaking initiative aimed at extending human lifespan by a decade through ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (LSE:0YC0) with a Buy recommendation. There are 52 funds or institutions reporting positions in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...